Literature DB >> 9137099

Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts.

A J Coito1, L F Brown, J H Peters, J W Kupiec-Weglinski, L van de Water.   

Abstract

Allograft rejection is associated with infiltration of inflammatory cells and deposition of extracellular matrix proteins. The extent to which diversity in the extracellular matrix regulates inflammatory cell function in transplants remains unclear. One group of extracellular matrix proteins, termed fibronectins (FNs), exhibits inherent diversity as a consequence of alternative splicing in three segments: EIIIA, EIIIB, or V. Although the EIIIA segment has documented functions in mesenchymal cell differentiation, neither this segment nor the EIIIB segment have been tested for effects specific to leukocyte functions. By contrast, the V region can include the CS-1 segment to which leukocytes may adhere through alpha 4 beta 1 integrins. In this study, we demonstrate that EIIIA+, EIIIB+, and V+ FN variants are synthesized, primarily by macrophages in distinct temporal and spatial patterns in two rat cardiac transplant models: either with antigenic challenge, allografts, or without challenge, isografts. The ratio of EIIIA inclusion into FN increases by day 1 in allografts and isografts and remains high until allografts are rejected (approximately 7 days) but falls to normal levels in tolerated isografts (day 6). EIIIB+ FN ratios in allografts peak later than do EIIIA+ FNs (day 4). EIIIB+ FN ratios remain relatively low in isografts. Interestingly, EIIIA+ and EIIIB+ FNs are deposited prominently in the myocardium of rejecting allografts in close association with infiltrating leukocytes, and FN expression and deposition are prominent at sites of infarction. By contrast, these FNs are largely restricted to the epicardium and to a lesser degree in the immediately adjacent myocardium in isografts. CS-1+ FNs increase in allografts and isografts at 3 hours after transplantation but are particularly prominent in allografts 1 to 3 days before rejection. Our data suggest that FN splicing variants have a differential role in the effector functions of leukocytes in allografts and isografts and provide a foundation for testing their function on leukocytes and a rationale for FN-based therapeutics to modulate allograft rejection in transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137099      PMCID: PMC1858214     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

1.  Equilibrium binding of cytotoxic T lymphocytes to class I antigen.

Authors:  M F Mescher; A M O'Rourke; P Champoux; K P Kane
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

Review 2.  Lymphocyte interactions with extracellular matrix.

Authors:  Y Shimizu; S Shaw
Journal:  FASEB J       Date:  1991-06       Impact factor: 5.191

Review 3.  Recognition of self within self: specific lymphocyte positioning and the extracellular matrix.

Authors:  M de Sousa; N L Tilney; J W Kupiec-Weglinski
Journal:  Immunol Today       Date:  1991-08

Review 4.  Adhesion receptors of the immune system.

Authors:  T A Springer
Journal:  Nature       Date:  1990-08-02       Impact factor: 49.962

Review 5.  Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation.

Authors:  Y Shimizu; G A van Seventer; K J Horgan; S Shaw
Journal:  Immunol Rev       Date:  1990-04       Impact factor: 12.988

6.  Lymphocyte traffic is modified in vivo by anti-laminin antibody.

Authors:  J W Kupiec-Weglinski; M De Sousa
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

7.  Affinity chromatographic isolation of the melanoma adhesion receptor for the IIICS region of fibronectin and its identification as the integrin alpha 4 beta 1.

Authors:  A P Mould; L A Wheldon; A Komoriya; E A Wayner; K M Yamada; M J Humphries
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

8.  Activation of human CD4 T lymphocytes. Interaction of fibronectin with VLA-5 receptor on CD4 cells induces the AP-1 transcription factor.

Authors:  A Yamada; T Nikaido; Y Nojima; S F Schlossman; C Morimoto
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

9.  Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts.

Authors:  S Molossi; M Elices; T Arrhenius; R Diaz; C Coulber; M Rabinovitch
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo.

Authors:  C Ffrench-Constant; R O Hynes
Journal:  Development       Date:  1989-06       Impact factor: 6.868

View more
  15 in total

1.  Fibronectin-mononuclear cell interactions regulate type 1 helper T cell cytokine network in tolerant transplant recipients.

Authors:  A J Coito; K Onodera; H Kato; R W Busuttil; J W Kupiec-Weglinski
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Fibronectin-alpha4beta1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury.

Authors:  Carolina Moore; Xiu-Da Shen; Feng Gao; Ronald W Busuttil; Ana J Coito
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  Fibronectin-α4β1 interactions in hepatic cold ischemia and reperfusion injury: regulation of MMP-9 and MT1-MMP via the p38 MAPK pathway.

Authors:  S Duarte; X-D Shen; C Fondevila; R W Busuttil; A J Coito
Journal:  Am J Transplant       Date:  2012-07-19       Impact factor: 8.086

4.  Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis.

Authors:  Adam J Booth; Sherri C Wood; Ashley M Cornett; Alyssa A Dreffs; Guanyi Lu; Andrés F Muro; Eric S White; D Keith Bishop
Journal:  J Pathol       Date:  2012-01-04       Impact factor: 7.996

5.  Fibronectin Splicing Variants Containing Extra Domain A Promote Atherosclerosis in Mice Through Toll-Like Receptor 4.

Authors:  Prakash Doddapattar; Chintan Gandhi; Prem Prakash; Nirav Dhanesha; Isabella M Grumbach; Michael E Dailey; Steven R Lentz; Anil K Chauhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-01       Impact factor: 8.311

6.  De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.

Authors:  Marcus Franz; Monika Matusiak-Brückner; Petra Richter; Katja Grün; Barbara Ziffels; Dario Neri; Hansjörg Maschek; Uwe Schulz; Alexander Pfeil; Christian Jung; Hans R Figulla; Jan Gummert; Alexander Berndt; André Renner
Journal:  J Mol Histol       Date:  2014-05-03       Impact factor: 2.611

7.  Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection.

Authors:  Marcus Franz; K Grün; P Richter; B R Brehm; M Fritzenwanger; K Hekmat; D Neri; J Gummert; H R Figulla; H Kosmehl; A Berndt; A Renner
Journal:  Histochem Cell Biol       Date:  2010-10-08       Impact factor: 4.304

8.  ACE2/Ang-(1-7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cells.

Authors:  Neha Singh; Shrinidh Joshi; Lirong Guo; Matthew B Baker; Yan Li; Ronald K Castellano; Mohan K Raizada; Yagna P R Jarajapu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

9.  Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF).

Authors:  Julia Brenmoehl; Werner Falk; Michael Göke; Jürgen Schölmerich; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2008-07-17       Impact factor: 2.571

10.  Cytoprotective effects of a cyclic RGD peptide in steatotic liver cold ischemia and reperfusion injury.

Authors:  C Fondevila; X-D Shen; S Duarte; R W Busuttil; A J Coito
Journal:  Am J Transplant       Date:  2009-07-22       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.